ScholarWorks@Dongguk University: Kim, Dong Eog

Detailed Information

Kim, Dong Eog (김동억)

Graduate School (Department of Medicine)

Research Area

Tel 031-961-7210
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

stroke:24||Stroke:22||ischemic stroke:18||Ischemic Stroke:15||Male:14||Female:12||Aged:11||cerebral infarction:11||Acute ischemic stroke:11||Human:9||acute ischemic stroke:9||Middle Aged:9||Ischemic stroke:9||atrial fibrillation:8||Treatment Outcome:8||Article:7||aspirin:7||atherosclerosis:7||Humans:7||magnetic resonance imaging:6||Controlled Study:6||Major Clinical Study:6||Cerebrovascular Accident:6||Multicenter Study:6||thrombolysis:6||Clinical Trial:5||Prognosis:5||Magnetic resonance imaging:5||clopidogrel:5||Acute Ischemic Stroke:5||Atherosclerosis:5||Brain Ischemia:5||South Korea:5||Thrombectomy:5||Atrial fibrillation:5||recurrence:5||prognosis:5||Prospective Study:5||Risk Factor:4||Hypertension:4||Molecular imaging:4||Homocysteine:4||Comparative Study:4||Nuclear Magnetic Resonance Imaging:4||Adult:4||Deep learning:4||molecular imaging:4||White Matter:4||myocardial infarction:4||Thrombolytic therapy:4||Magnetic Resonance Imaging:3||Brain Infarction:3||Nerinetide:3||Early vascular outcome:3||Cohort Analysis:3||mortality:3||blood pressure:3||Prevalence:3||Brain:3||endovascular treatment:3||computed tomography:3||white matter hyperintensities:3||outcome:3||Thrombolysis:3||Cerebral infarction:3||Stroke Patient:3||Mouse:3||Depression:3||propensity score:3||outcome assessment:3||Diagnostic Imaging:3||heart rate:3||Disease Severity:3||leukoaraiosis:3||LDLcholesterol:3||microCT:3||National Institutes Of Health Stroke Scale:3||Cerebrospinal Fluid:3||Rankin Scale:3||Registries:2||thrombectomy:2||cohort study:2||thrombus imaging:2||Reproducibility:2||tissuetype plasminogen activator:2||Republic Of Korea:2||Republic of Korea:2||Leukocyte Count:2||death:2||Asia:2||Anger:2||Diffusion Weighted Imaging:2||direct thrombus imaging:2||Rnf213 Protein, Human:2||Diffusion magnetic resonance imaging:2||MMP9:2||Serine Protease Htra1:2||Biomarkers:2||early neurological deterioration:2||Animal:2||endovascular recanalization:2||Matrix metalloproteinase:2||Heart failure:2||Skull:2||Cardiovascular diseases:2||Hematopoiesis:2||Mice:2||gold nanoparticle:2||gold nanoparticles:2||Middle Cerebral Artery Occlusion:2||Hightemperature Requirement A Serine Peptidase 1:2||Acute stroke:2||Animal Model:2||Cerebral Infarction:2||Htra1 Protein, Human:2||Multidrug Resistance Associated Protein 6:2||hypertension:2||Mutation:2||Stroke subtype:2||Nanomedicine:2||Cerebral infarct:2||Hydroxymethylglutarylcoa Reductase Inhibitors:2||Thrombosis:2||Thrombus imaging:2||Neuroimaging:2||Tissue plasminogen activator:2||large artery atherosclerosis:2||largevessel occlusion:2||Transient:2||Basilar Artery:2||Nonhuman:2||Ubiquitin Protein Ligase:2||Ubiquitinprotein Ligases:2||Animals:2||Incidence:2||Infarct Volume:2||Outcome Assessment:2||Cholesterol, Ldl:2||Vascularization:2||Outcome assessment:2||Very Elderly:2||mild stroke:2||Circadian Rhythm:2||Aged, 80 And Over:2||Anticoagulants:2||Severity Of Illness Index:2||Clinical Outcome:2||acute minor stroke:2||Clinical Research:2||Pathology:2||Blood Cell Count:2||Patient Acuity:2||Activin Receptors, Type Ii:2||perfusion imaging:2||Algorithm:2||Physiology:2||Acvrl1 Protein, Human:2||prediction:2||Body mass index:2||prevention:2||Intravenous Thrombolysis:2||Computed tomography:2||Intravenous thrombolysis:2||Bone Marrow:2||registries:2||risk factors:2||Ischemic Attack:2||secondary prevention:2||bloodbrain barrier:2||Prospective Studies:2||Adenosine Triphosphatase:2||Adenosine Triphosphatases:2||Korea:2||Arteriosclerosis:2||Brain Hemorrhage:2||Deep Learning:2||Left atrial appendage closure:1||Letter:1||Lipid paradox:1||Lipid ratio:1||Long Term Care:1||Low Density Lipoprotein Cholesterol:1||Low Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score:1||Lymphocyte:1||Lymphocytes:1||MRI:1||Machine learning:1||Magnetic Resonance Angiography:1||Medical Record:1||Medical complications:1||Medicine:1||Meningitis, Bacterial:1||Menkes disease:1||Mild stroke:1||Minor Ischemic Stroke:1||Modified Rankin Scale:1||Monocyte deficiency:1||Monogenic Disorder:1||Mortality:1||NIHSS:1||Nanoparticle:1||Needle Time:1||Neural stem cell:1||Neurogenesis:1||Neurologic Disease:1||Neurologic Disease Assessment:1||Neurovascular:1||Nontraditional lipid profiles:1||Notch3 Receptor:1||Obesity paradox:1||Observational Study:1||Oral anticoagulant:1||Outcome:1||Outcome after stroke:1||Outcomes:1||Ovariectomy:1||Oxiracetam:1||PSD95:1||Parietooccipital Sulcus:1||Patent foramen ovale closure:1||Pathophysiology:1||Penumbra:1||Percutaneous Thrombectomy:1||Perivascular Space:1||Physician training:1||Plaque:1||Plaque imaging:1||Platelet aggregation inhibitors:1||Pneumococcal Meningitis:1||Polycythemia Vera:1||Positronemission tomography:1||Preceding intravenous thrombolysis:1||Preclinical Study:1||Procedures:1||Propensity Score:1||Prophylaxis:1||Proprotein Convertase 9:1||Protein engineering:1||Proteolytic enzymes:1||Pulmonary Arteriovenous Fistula:1||Puncture Time:1||Rat:1||Recanalization:1||Recovery Of Function:1||Recurrent event:1||Reference standards:1||Register:1||Reperfusion:1||Reperfusion Injury:1||Reproducibility Of Results:1||Residual cardiovascular risk:1||Retrospective Studies:1||Retrospective Study:1||Revascularization:1||Risk Assessment:1||Risk Factors:1||Risk score:1||Seasonal Variation:1||Sensitivity Analysis:1||Serine Proteinase:1||Sex:1||Sex Characteristics:1||Sex Difference:1||Sex Ratio:1||Sexual Characteristics:1||Silent brain infarction:1||Silicacoated gold nanoparticle:1||Singleenergy CT:1||Small Vessel Occlusion:1||Small vessel occlusion:1||Smoking:1||Statin pretreatment:1||Statins:1||Statistics:1||Stem cell imaging:1||Stenosis:1||Streptococcus Pneumoniae:1||Striatocapsular Lesion:1||Stroke Recurrence:1||Stroke Unit:1||Stroke imaging:1||Stroke onset:1||Stroke progression:1||Stroke recurrence:1||Stroke registry:1||Stroke severity:1||Subgroup analysis:1||Systolic Blood Pressure:1||Taiwan:1||Telephone Interview:1||Tenecteplase:1||Therapeutic benefit:1||Thrombinactivatable fluorescent probe:1||Thrombolytic Therapy:1||Tibia:1||Time Factor:1||Time Factors:1||Tissueplasminogen activator:1||Transient Ischemic Attack:1||Tumor Necrosis Factor:1||UVvis spectroscopy:1||Unclassified Drug:1||Underweight:1||Utilization:1||Vascular cognitive impairment:1||Vascular dementia:1||Vascular outcome:1||Vascular surgery:1||Venous thromboembolism:1||Vulnerable plaque:1||Waist circumference:1||Xray Computed Tomography:1||acute isc hemic stroke:1||acute ischaemic stroke:1||acute myocardial infarction:1||acute stroke:1||advanced treatments:1||age:1||air pollution:1||amyloid deposition:1||anemia:1||angiography:1||anticoagulation:1||antiplatelet:1||antiplatelet agents:1||antiplatelet drugs:1||antiplatelets:1||apolipoproteins:1||arrhythmias, cardiac:1||arterial thrombosis:1||assessment, patient outcome:1||asymmetry:1||atorvastatin:1||basilar artery:1||beta blocker:1||bioorthogonal click chemistry:1||brain frailty:1||brain ischemia:1||brain macrobleed:1||brain stroke:1||carotid artery occlusion:1||carotid intima media thickness:1||carotid plaque:1||cathepsinB:1||cerebral microinfarct:1||cholinergic fibers:1||clinical inertia:1||clinical outcomes:1||clinical trial:1||clinical trials:1||clopidogrelaspirin:1||cohort studies:1||collateral circulation:1||comparative effectiveness research:1||complete blood count (CBC):1||computed tomography angiography:1||connectome:1||coronary heart disease:1||deep learning:1||deeplearning algorithm:1||dementia:1||demography:1||depression:1||diabetes:1||diagnosis:1||disparity:1||dissection:1||dripandship:1||dual antiplatelet treatment:1||dual antiplatelets:1||dualmodal imaging:1||early vascular outcomes:1||embolic stroke:1||embolic stroke of undetermined source:1||embolism:1||endovascular therapy:1||epidemiology:1||escitalopram:1||exercise:1||fibrintargeted gold nanoparticle:1||genedepression:1||gintonin:1||glial scar formation:1||global longitudinal peak strain:1||glucocorticoids:1||glycated hemoglobin (hbA1c):1||glycol chitosan:1||groupbased trajectory model:1||guideline adherence:1||health services research:1||hematopoietic stem cells:1||hemoglobins:1||hemorrhage:1||hemorrhagic transformation:1||hemostatic:1||heparin:1||history of intracerebral hemorrhage:1||hospital performance:1||humans:1||hyperintense vessel sign:1||imaging probe:1||incidence:1||inflammation:1||infusion:1||interventional neuroradiology:1||intima:1||intraarterial:1||intracranial atherosclerosis:1||intracranial hemorrhage (ICH):1||intracranial stenosis:1||intravenous thrombolysis:1||intravital imaging:1||iopromide:1||ischaemic stroke:1||ischemic:1||ischemic attack, transient:1||lacunar infarct:1||lacunar stroke:1||lacunes:1||late‐presenting stroke:1||left atrial volume index:1||lipids and lipoproteins:1||lipopolysaccharide:1||low NIHSS score:1||lowdose tPA:1||lymphocyte:1||machine learning:1||macrophage:1||magnetic resonance angiography:1||magnetic resonance image:1||major vascular event:1||management:1||media thickness:1||metabolic engineering:1||microCT:1||microbleeds:1||migraine:1||motor recovery:1||multicenter registry:1||multicenter studies:1||nearinfrared fluorescent imaging:1||neural network:1||neural networks:1||neural pathways:1||neuroimaging:1||neuroprotective:1||nitric oxide synthase:1||nonminor stroke:1||oligemia:1||oxiracetam:1||particulate matter:1||pharmacokinetics:1||photodynamic therapy:1||photosensitizer:1||physical activity:1||plateletderived growth factor:1||prestroke glycemic status:1||proportional hazards models:1||prospective cohort study:1||prospective studies:1||proteasemediated theranostic agent:1||pulse pressure:1||quality:1||randomized:1||randomized clinical trial:1||reactive astrocyte:1||risk:1||risk score:1||rosuvastatin:1||safety:1||seconadry stroke prevention:1||secular trend:1||segmentation algorithm:1||serotonin:1||small vessel disease:1||speckletracking imaging echocardiography:1||staining:1||statin:1||stem cell tracking:1||stroke care:1||stroke etiology:1||stroke mechanism:1||stroke recurrence:1||stroke registry:1||stroke subtype:1||strongly annotated dataset:1||symptomatic hemorrhagic transformation:1||syndrome:1||tMCAO:1||temporal trends:1||thrombus evolution:1||time in therapeutic range:1||time to treatment:1||timetotreatment:1||topographic brain mapping:1||transient ischemic attack:1||treatment:1||treatment duration:1||treatment intensification:1||trends:1||triage:1||tumor targeting:1||ultrasonography:1||vascular cognitive impairment:1||vascular death:1||vascular event:1||warfarin:1||weighted ensemble model:1||white blood cell (WBC) differential count:1||white matter disease:1||whitematter hyperintensity:1||.:1||young adult:1||2,3,5 Triphenyl Tetrazolium Chloride:1||2,3,5Triphenyltetrazolium chloride:1||3 to 4.5hour time window:1||ASPECTS:1||ATP7A:1||Abdominal obesity:1||Activin Receptor 2:1||Activin Receptor Like Kinase 1:1||Acute stroke therapy:1||Admission hyperglycemia:1||Admission route:1||Age:1||Aging:1||Algorithms:1||All Cause Mortality:1||Alteplase:1||Anesthesia:1||Angiography:1||Animal Cell:1||Animal Experiment:1||Animal Tissue:1||Anticoagulant Agent:1||Anticoagulation:1||Antiplatelet:1||Antiplatelet drugs:1||Antithrombotic:1||Apoptosis imaging:1||Artificial intelligence:1||Asia, Eastern:1||Atheroma:1||Atherosclerotic stroke:1||Atrial Fibrillation:1||Bacterial Growth:1||Bacterial Load:1||Bacterial Meningitis:1||Basilar Artery Occlusion:1||Behavior change:1||Biological Marker:1||Blood Clot Lysis:1||Blood Sampling:1||Blood pressure:1||Brain Angiography:1||Brain Blood Flow:1||Brain Circulus Arteriosus:1||Brain Damage:1||Brain Infarction: Recovery of Function:1||Brain Mapping:1||CRCSK:1||CTcontrast agent:1||Cancer:1||Cardioembolism:1||Cardiovascular disease:1||Case profile:1||Cerebellum Injury:1||Cerebral Artery Stenosis:1||Cerebrocortical Lesion:1||Cerebrospinal Fluid Flow:1||Cha2ds2vasc Score:1||Classification:1||Clinical Effectiveness:1||Clinical Feature:1||Clinical Study:1||Clinical trial:1||Cohort Studies:1||Collagen Type 3:1||Comparative effectiveness research:1||Computer Assisted Diagnosis:1||Conservative Treatment:1||Convalescence:1||Cumulative Incidence:1||Cytokine:1||Cytokines:1||DWIASPECTS:1||Deep vein thrombosis:1||Deglutition:1||Deglutition disorders:1||Demography:1||Dendrimers:1||Diabetes mellitus:1||Diffusionweighted image:1||Diffusionweighted imaging:1||Direct thrombus imaging:1||Disease Exacerbation:1||Disease Progression:1||Disks Large Homolog 4:1||Disparity:1||Domain adaptation:1||Drug Repurposing:1||Dual antiplatelet therapy:1||Dual optical/CT imaging:1||Dualenergy CT:1||Dyslipidemia:1||END management:1||Early neurologic deterioration:1||Elderly:1||Electrocardiography:1||Emotional incontinence:1||Emotions:1||Endovascular Procedures:1||Endovascular Surgery:1||Endovascular Treatment:1||Endovascular therapy:1||Endovascular treatment:1||Escitalopram:1||Event Outcome:1||Ex Vivo Study:1||Exercise:1||Exercise training:1||Extracranial:1||FDGPET/CT:1||FHL2 (Four And A Half LIM Domains 2):1||Family History:1||Federated learning:1||Fibrinolytic Therapy:1||Fluidattenuated Inversion Recovery Imaging:1||Fluidattenuated inversion recovery:1||Follow Up:1||Followup Studies:1||Fracture:1||Functional MRI:1||Functional Outcome:1||Functional Status:1||Functional outcome:1||Futile reperfusion:1||GSK3:1||Gastrointestinal bleeding:1||Gene Mutation:1||Genetic Variability:1||Genetics:1||Glucose Blood Level:1||Glymphatic System:1||Greenchannel autofluorescence imaging:1||HDAC:1||Hematocrit:1||Hemoglobin:1||High Throughput Sequencing:1||Hippocampus:1||Holter Monitoring:1||Hospital Admission:1||Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor:1||Hyperacute treatment:1||Hyperlipidemia:1||Image Interpretation, Computerassisted:1||Image segmentation:1||Imaging agents:1||In Vivo Study:1||In vivo imaging:1||Infarct volume:1||Infarction:1||Inflammation imaging:1||Informed Consent:1||Interhospital transfer:1||Interleukin 1beta:1||Interleukin 6:1||Internal Carotid Artery:1||Internal Carotid Artery Occlusion:1||Internal Carotid Artery Stenosis:1||Intimamedial thickness:1||Intracranial:1||Intracranial Hemorrhages:1||Intracranial arterial stenosis:1||Intracranial hemorrhages:1||Intravenous recombinant tissue plasminogen activator:1||Intravital two photon microscopy:1||Iodinated contrast agents:1||Ischaemic stroke:1||Ischemic Attack, Transient:1||Ischemic brain lesion:1||Issue 115:1||LDLC:1||LDL/HDL ratio:1||Large artery stenoocclusion:1||Laser Doppler Flowmetry:1||Lateral medullary syndrome:1||Learning Algorithm:1||

RSS_1.0 RSS_2.0 ATOM_1.0

30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE